
Stevens has started three biotechnology companies (Syrrx (1999), MemRx (2002), and Receptos (2009)), all focused on structure based drug discovery. The company Syrrx was acquired by Takeda Pharmaceuticals in 2005 for the high-throughput structure based drug discovery platform, and because of a phase II clinical candidate alogliptin known to inhibit the enzyme DPPIV and is [...]









